Please find attached the Audited Standalone and Consolidated Financial Results for the financial year ended March 31, 2025
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Sudarshan Pharma Industries reported strong standalone revenue growth of ~36% to ₹22,535 lakhs in FY25 (vs ₹16,556 lakhs in FY24), driven by API manufacturing, job-work and chemicals trading. Consolidated revenue grew more modestly by ~5% to ₹27,726 lakhs. However, net profit declined ~12% on both standalone (₹995.86 lakhs vs ₹1,135.53 lakhs) and consolidated (₹1,003.10 lakhs vs ₹1,145.53 lakhs) bases, as rising costs compressed operating margins. The company booked ₹164.81 lakhs as an exceptional loss from waterlogging damage at its Bhiwandi warehouse, after the insurance claim of ₹281.73 lakhs was rejected. The promoter group was allotted 9 lakh convertible warrants (₹169.83 each, ~₹15.28 crore), and the company completed acquisitions of a Singapore subsidiary and 51% of Ishwari Healthcare. A ₹9.19 crore Dubai court award in its favour remains pending recovery.
Mixed picture for shareholders — strong top-line growth signals business expansion, but contracting margins and falling profits may weigh on the stock in the short term. The promoter warrant allotment is confidence-boosting but will dilute equity if converted, and the rejected insurance claim and pending Dubai recovery add earnings uncertainty.